Enteris BioPharma


MOD3 Pharma is a fully integrated contract development and manufacturing organization (CDMO) specializing in innovative drug delivery solutions for Orally Inhaled and Nasal Drug Products (OINDP). Supported by decades of CMC experience, the company focuses on transforming investigational drugs into clinic-ready products through stage-appropriate methodologies, advanced formulation science, and quality manufacturing. As a subsidiary of SWK Holdings, MOD3 Pharma emphasizes regulatory excellence, scientific innovation, and collaborative partnerships to accelerate drug development from feasibility to early phase clinical trials.

Industries

biopharma
biotechnology
health-care
pharmaceutical

Nr. of Employees

small (1-50)

Enteris BioPharma

Boonton, New Jersey, United States, North America


Services

Consulting

Regulatory and CMC consulting for drug development, including Module 3 preparation, CMC strategy, and project-level problem solving across development stages.

Product Development

Formulation development, spray drying, particle engineering, and analytical method development and validation to advance drug products toward clinic readiness.

Clinical Supplies

cGMP manufacture of clinical trial materials, small-batch commercial supplies, finished product release and stability testing, labeling, and blinding for early-phase studies.

Expertise Areas

  • Orally inhaled and nasal drug product (OINDP) development
  • Chemistry, Manufacturing and Controls (CMC) strategy
  • Early-phase clinical supply manufacturing (Phase 1 & 2)
  • Formulation science and bioavailability enhancement
  • Show More (4)

Key Technologies

  • Spray drying
  • Particle engineering / post-processing
  • Semi-automated filling and assembly
  • Single-dose and multi-dose nasal delivery systems
  • Show More (6)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.